Find Academic Supervisors

Dan LizotteView profile

Associate Professor

• Reinforcement Learning
• Machine Learning
• Statistical Methods
• +7 more

Dan Lizotte is an Associate Professor with appointments in the Department of Computer Science and the Department of Epidemiology and Biostatistics at Western University. He is also affiliated with the Schulich Interfaculty Program in Public Health, cross-appointed to the Department of Statistics and Actuarial Sciences, and serves as Associate Faculty in the Rotman Institute of Philosophy. His work bridges computer science, statistics, and public health, focusing on the application of advanced computational methods to healthcare decision-making. Dr. Lizotte earned his BCS from New Brunswick and completed his MSc and PhD in Computer Science at Alberta. His educational background in computer science forms the foundation for his interdisciplinary research that applies machine learning and statistical techniques to health data. Professor Lizotte's research aims to adapt and improve reinforcement learning, machine learning, and statistical techniques for application to health data, providing stakeholders with evidence for non-myopic health decision making. He is particularly interested in problems involving multiple outcomes, causal inference, and outlier detection in public health and primary health care. His work spans artificial intelligence, biostatistics, and public health, with a growing focus on health equity and intersectionality in AI applications. Analysis of Dr. Lizotte's recent publications reveals a strong focus on applying machine learning and statistical methods to healthcare challenges. His work spans predictive modeling for chronic diseases, AI implementation in primary care, intersectionality in health research, and reinforcement learning for decision support. Recent trends show increasing attention to health equity, the application of AI to marginalized populations, and methodological innovations in handling complex health data with multiple outcomes. Dr. Lizotte has secured significant research funding including: Machine learning methodology for sequential decision support from largescale longitudinal data (NSERC; 2018-2024) Reinforcement Learning Methodology for Decision Analysis and Support in Long-term Care (NSERC; 2021-2022) Beyond Supervised Learning: Artificial Intelligence Tools to Help Public Health Stakeholders Serve Marginalized Populations (CIHR; 2019-2023) Artificial Intelligence for Public Health (AI4PH) Training Platform [co-Applicant with lead Dr. Laura Rosella] (CIHR; 2022-2026) Dr. Lizotte leads the Biostatistical & Computational Methods research cluster, which focuses on developing and applying advanced statistical and computational techniques to health data. His team works at the intersection of computer science, statistics, and public health to create decision support tools that can handle complex, real-world healthcare scenarios with multiple outcomes and considerations.

Mary PaineView profile

Professor

• Clinical pharmacology
• Pharmacokinetics
• Natural product-drug interactions
• +3 more

Dr. Mary Paine is a Professor in the Department of Pharmaceutical Sciences at Washington State University's College of Pharmacy and Pharmaceutical Sciences. She also serves as Director of Industry Advancement and leads the NIH-funded Center of Excellence for Natural Product Drug Interaction Research (NaPDI Center). Education: BS in Pharmacy, Oregon State University PhD in Pharmaceutics, University of Washington Post-Doctoral Fellowship in Clinical Pharmacology, University of Michigan Research Focus: Dr. Paine's research centers on clinical pharmacology and pharmacokinetics, particularly the interactions between natural products (including botanical dietary supplements and foods) and pharmaceutical drugs. Her translational research approach combines human-derived experimental systems, mathematical modeling, and clinical studies to predict and assess these complex interactions, aiming to improve patient safety and inform evidence-based healthcare practices. Publications: Her recent work (2020-2024) demonstrates a strong focus on cannabinoid-drug interactions, kratom pharmacokinetics, and methodological advancements in predicting natural product-drug interactions. Key themes include the development of physiologically-based pharmacokinetic (PBPK) models, clinical assessments of botanical substances like kratom and cannabis, and the integration of computational approaches for interaction prediction. Scientific Awards: 2021 ASCPT & FDA William B. Abrams Award 2023 ASCPT Rawls-Palmer Progress in Medicine Award Leadership & Service: Dr. Paine holds leadership roles in professional organizations including Co-Vice Chair of the Membrane Transporter Community (ASCPT) and Treasurer of the International Society for the Study of Xenobiotics. She serves as Associate Editor for Drug Metabolism and Disposition and has previously served as Associate Editor for Clinical Pharmacology & Therapeutics . She is also a member of the Scientific Advisory Board for Simcyp Certara and the Washington State Academy of Sciences. Research Team & Collaborations: Through the NaPDI Center, she leads a multidisciplinary team comprising clinical pharmacologists, natural products chemists, bioinformaticists, and health communications experts. The center's current focus includes investigating interactions involving cannabis, goldenseal, kratom, cinnamon, and oregano.

Jessica RodgersView profile

Assistant Professor

• Medical Physics
• Biomedical Engineering
• Radiation Oncology
• +3 more

Jessica Rodgers is an Assistant Professor in the Department of Physics and Astronomy at the University of Manitoba. She joined the department in 2022 after completing a postdoctoral fellowship in the School of Computing at Queen’s University. Her research focuses on developing clinically translatable medical physics tools, particularly improving cancer treatment through computer-assisted interventions such as image-guided radiotherapy and surgical navigation systems. Dr. Rodgers holds a PhD in Biomedical Engineering from Western University (2021) and a BSc in Mathematics and Engineering from Queen’s University (2014). Her work integrates engineering principles with medical applications, emphasizing technologies like 3D ultrasound imaging and deep learning for precision oncology. Her research interests include gynecologic and prostate cancer therapies, intraoperative margin assessment, and automated systems for brachytherapy planning. Recent studies involve 3D ultrasound fusion for brachytherapy guidance, automated catheter tracking, and mass spectrometry-based surgical navigation. These projects highlight her focus on bridging advanced imaging technologies with clinical oncology practice. Publications emphasize innovations in medical imaging workflows, including tools for needle guidance during brachytherapy, real-time cautery monitoring during surgery, and open-source software for mass spectrometry data analysis. This reflects her commitment to advancing both technical and translational aspects of medical physics. Dr. Rodgers has not yet listed any awards or grants in the provided information. Her advising activities are also currently unspecified, but her research group likely involves collaborations across engineering, physics, and medical disciplines.

• Health Informatics
• Health Information Management
• Telehealth
• +5 more

Shannon Houser is a Professor in the Department of Health Services Administration at the University of Alabama at Birmingham (UAB), School of Health Professions. She also holds secondary appointments as a Senior Scientist at multiple UAB research centers, including the Center for AIDS Research and the Center for Clinical and Translational Science. Her academic career spans over two decades, with tenure as Associate Professor (2004–2019) and Assistant Professor (2004–2009). Dr. Houser earned her PhD in Public Health (Health Behavior) and an MPH in Epidemiology from UAB, alongside a B.S. in Health Information Management. Her research focuses on health information management, telehealth, data analytics, and global health. Notable contributions include pioneering work on telehealth privacy and security, machine learning in healthcare, and HIV/AIDS research. She chairs international committees like the IFHIMA Education Community of Practice and serves as an editorial board member for journals such as Perspectives in Health Information Management . Dr. Houser’s awards include the AHIMA Triumph Award (2024, 2021), FAHIMA designation (2015), and recognition for global health contributions. She has published over 70 peer-reviewed articles, edited textbooks, and developed toolkits like the AHIMA Telehealth Toolkit . Her professional service spans leadership roles in AHIMA, HIMSS, and AUPHA, alongside mentoring students and fostering international collaborations, notably at Tsinghua University in China. Key grants and projects include work on HIV care monitoring, Project HOPE evaluations, and curriculum development in health informatics. Labs/Teams: Active in UAB’s Center for AIDS Research, Center for Outcomes and Effectiveness Research and Education (COERE), and the Sparkman Center for Global Health. Collaborates internationally on health data literacy and telehealth innovation.

• Nephrology
• Kidney Disease Research
• Dialysis
• +5 more

Professor David Johnson is a leading nephrologist serving as Director of the Metro South Kidney and Transplant Service (MSKATS) and Medical Director of the Queensland Kidney Transplant Service (QKTS) at Princess Alexandra Hospital. He holds dual professorships in Medicine and Population Health at the University of Queensland and directs the Centre for Kidney Disease Research in Brisbane. Internationally, he co-chairs the International Society of Nephrology Global Kidney Health Atlas, the International Society for Peritoneal Dialysis Guidelines on Peritonitis Prevention and Treatment, and the Global PDOPPS Steering Committee. Previously, he served as President of the ISPD (2018-2020) and Councillor of the ISN (2013-2019). Professor Johnson earned his MB BS with Honors and University Medal, followed by a PhD from Sydney University and a Doctor of Medical Research degree. He is a Fellow of the American Society of Nephrology (FASN), International Society of Nephrology (FISN), Australian Academy of Health and Medical Sciences (FAHMS), and Royal Australasian College of Physicians (FRACP). His research focuses on advancing kidney disease care through clinical trials, quality improvement initiatives, and global health policy. Professor Johnson has published over 1,200 peer-reviewed manuscripts and led landmark studies including CKD-FIX, IDEAL, and balANZ trials that have shaped international clinical practice. His work spans dialysis techniques, kidney transplantation, early detection of kidney disease, and implementation of evidence-based practices in diverse healthcare settings worldwide. Professor Johnson's recent publications reveal a continued focus on global kidney health disparities, peritoneal dialysis outcomes, and innovative approaches to managing kidney disease complications. His work with the ISN-GKHA highlights regional variations in kidney care access and quality, while his clinical trials continue to refine optimal dialysis and transplantation strategies. His research increasingly incorporates geriatric considerations for older adults with kidney disease and addresses health equity issues for Indigenous and marginalized populations. ANZSN TJ Neale Award for "outstanding contributions to nephrologic science" (2005) US National Kidney Foundation International Distinguished Medal (2014) Canadian Society of Nephrology Dimitrios Oreopoulos Award (2017) Asia-Pacific Society of Nephrology Priscilla Kincaid-Smith Award (2021) Queensland finalist in the Australian of the Year Awards (2009) Public Service Medal by the Governor-General of Australia (2011) Professor Johnson has led numerous high-impact, multi-center randomized controlled trials that have informed global clinical practice, including CKD-FIX, IDEAL, balANZ, HONEYPOT, TESTING, HERO, and IMPENDIA. He currently serves as principal investigator for the TEACH-PD and INCH-HD trials and chairs the PHOSPHATE Trial Global Steering Committee. His research has been supported by major national and international funding bodies, enabling him to establish significant infrastructure including the Australian Peritonitis Registry and implement nationwide quality improvement initiatives that reduced peritonitis rates by two-thirds. As Director of the Centre for Kidney Disease Research, Professor Johnson leads a multidisciplinary team focused on improving kidney health outcomes through innovative research and implementation science. His team successfully established the Australian Peritonitis Registry and led the National PD Peritonitis Quality Improvement Project. He also spearheaded the universal implementation of automated laboratory reporting of eGFR in Australia and New Zealand, which increased national detection rates of kidney disease by 40%. His work with the International Society of Nephrology's Global Kidney Health Atlas team provides critical insights into worldwide kidney care capacity and disparities.

• Radiation Dosimetry
• Medical Physics
• Radiotherapy
• +5 more

Dagmara Kulig, PhD, Eng., serves as a Lecturer at the Department of Particle Interactions and Detection within the Faculty of Physics and Applied Computer Science at AGH University of Science and Technology in Kraków, Poland. Her research focuses on advancing radiation measurement technologies for medical applications, particularly in radiotherapy quality assurance and dosimetry innovation. Her primary research domains include Radiation Dosimetry, Medical Physics, and Radiotherapy, with specialized expertise in Optically Stimulated Luminescence (OSL) and Thermoluminescence (TL) phenomena. Kulig investigates novel luminescent materials—especially LiMgPO 4 -based compounds—and develops 3D-printed scintillators for precise dose measurement. Her work bridges experimental physics with clinical oncology through computational modeling and deep learning applications for treatment planning optimization. Analysis of her 15 most recent publications (2016-2025) reveals a consistent trajectory in radiation monitoring systems, with increasing emphasis on modular detector architectures and AI-driven medical imaging. The Dose-3D project represents a significant computational contribution, while her material science work on LiMgPO 4 dosimeters addresses critical challenges in signal stability and sensitivity. Recent publications demonstrate growing integration of 3D printing and deep learning for personalized radiotherapy solutions. Scientific awards: No awards documented in provided information Advising and grants: No student supervision details available No external funding sources specified Laboratory engagement: Core contributor to Dose-3D project developing Monte Carlo simulation platforms Experimental work on radiation detector systems at Department of Particle Interactions and Detection Material synthesis and characterization for luminescent dosimeters

Régine GSCHWINDView profile

Professor

• Dosimetry
• Radiation Protection
• Radiotherapy
• +4 more

Régine GSCHWIND is a Professor at the Université Bourgogne Franche-Comté, based at the Montbéliard site of UMR 6249 Chrono-environnement. Her research focuses on developing absorbed dose calculation methods combining artificial intelligence and Monte Carlo simulation, alongside 3D dosimetry using gels in external radiotherapy. She leads the Montbéliard site and collaborates on projects like PHC Toubkhal (France-Maroc) studying photo-neutrons in medical linear accelerators, and Fadogel evaluating low-dose exposure via nanoparticle-doped gels. Her work spans dosimetry, radiation protection, and radiotherapy optimization, with recent emphasis on AI-driven dose prediction and advanced film calibration techniques. Key contributions include feasibility studies of MR-Linac systems and pediatric radiation exposure analyses. Scientific awards: None explicitly listed. Advising and grants: Supervises student Malek Ould Mohand. Research projects include collaborations on radon exposure management and medical radiation safety practices. Her lab, Chrono-environnement, integrates environmental and medical physics expertise.

Claire VilleneuveView profile

Researcher

• Pharmacometrics
• Therapeutic education
• Treatment adherence
• +4 more

Claire Villeneuve is a Clinical Research Engineer at INSERM U1248 P&T and a Hospital Engineer at CHU of Limoges . Affiliated with the School of Medicine and Pharmacy at Université de Limoges, her work focuses on pharmacometrics and therapeutic education in transplantation. Research Themes : Individualized treatment dosing, patient empowerment, adherence analysis, quality of life optimization, and pharmacokinetic modeling in transplant recipients Methodological Expertise : Psychometric validation of patient-reported outcome tools, SNDS database applications, and multi-scale pharmacokinetic modeling Scientific Contributions include studies on: CMV prophylaxis cost-effectiveness Tacrolimus exposure-toxicity relationships CIP code utilization in health reimbursement systems Quality of life trajectories post-transplant Adherence profiles in renal transplant patients Teaching Activities encompass scale methodology education for healthcare professionals and clinical trial regulations instruction for IADE students.

• Radiation Dosimetry
• Medical Physics
• FLASH Radiotherapy
• +7 more

Maurizio Marrale serves as Associate Professor in the Department of Physics and Chemistry at the University of Palermo (Unipa), holding position PHYS-06/A. His office is located at the Department of Physics and Chemistry "Emilio Segre" (DIFC), Viale delle Scienze, Building 18, with regular office hours on Thursdays from 3:00 PM to 5:00 PM. His research spans radiation dosimetry, medical physics, and advanced imaging techniques. Key focus areas include FLASH radiotherapy verification using alanine/EPR dosimetry and silicon carbide detectors, transcranial magnetic resonance-guided focused ultrasound for neurological disorders (particularly essential tremor), and MRI-based dosimetry with Fricke gels. His work bridges physics principles with clinical applications in radiation oncology and diagnostic imaging. Analysis of his 15 most recent publications reveals strong emphasis on Ultra-high dose rate (UHDR) beam characterization for FLASH radiotherapy Development of novel dosimetry systems (SiC detectors, ionoacoustic sensors) Advanced neuroimaging techniques for thalamic targeting Diffusion correction methodologies in 3D dosimeters Clinical MRI applications for neurological disorders His research demonstrates consistent integration of computational modeling (Geant4, deep learning) with experimental validation. As principal supervisor, he has guided over 35 master's theses at Unipa between 2009-2024, primarily in Physics and Medical Radiology Techniques programs. His supervisory work focuses on radiation dosimetry applications, MRI physics, and radiotherapy technology validation.

Daniel J. CronaView profile

Assistant Professor

• Clinical Pharmacology
• Epigenetics
• Developmental Therapeutics
• +3 more

Daniel J. Crona is an Assistant Professor in the Division of Pharmacotherapy and Experimental Therapeutics at the University of North Carolina Eshelman School of Pharmacy and a member of the UNC Lineberger Comprehensive Cancer Center. His research integrates epigenetics, developmental therapeutics, and clinical pharmacology to optimize treatment strategies for hematology/oncology patients through a functional genomics paradigm. Dr. Crona's work focuses on revealing molecular mechanisms underlying the interplay between patient genotype, phenotype, and epigenetics, then integrating this information with clinical pharmacology principles including pharmacokinetics and pharmacodynamics to optimize drug selection and dosing. His research spans precision dosing, pharmacogenomics, cancer therapeutics, and management of drug-related toxicities, with applications across multiple therapeutic areas in oncology. Hematology/Oncology Pharmacy Association Early Career Research Award (2019) IBM Junior Faculty Development Award (2019) American College of Clinical Pharmacy Research Institute Junior Investigator Award (2018) GlaxoSmithKline Dissertation Fellowship (2014) Kathryne A. Brewington Award for Outstanding Graduate Student (2014) As a member of the UNC Lineberger Comprehensive Cancer Center, Dr. Crona collaborates with multidisciplinary research teams to advance cancer therapeutics through precision medicine approaches. His work bridges basic science discoveries with clinical applications to improve patient outcomes in oncology, with particular emphasis on translating pharmacogenomic findings into clinical practice.

Tim WiltshireView profile

Associate Professor

• Pharmacogenetics
• Precision Medicine
• Clinical Pharmacology
• +4 more

Dr. Tim Wiltshire is an Associate Professor at the University of North Carolina at Chapel Hill School of Pharmacy, where he conducts research in pharmacogenetics and personalized medicine. He leads the Wiltshire Laboratory and is affiliated with the UNC Institute for Pharmacogenomics and Individualized Therapy (CPIT). His work focuses on translating pharmacogenetic knowledge into clinical practice to improve medication safety and efficacy. Dr. Wiltshire's research spans multiple areas of pharmacogenomics, with particular emphasis on: Predicting drug response and adverse events using genetic information Developing clinical implementation strategies for pharmacogenetic testing Personalized dosing approaches for medications across various therapeutic areas Pharmacogenomic applications in vulnerable populations including nursing home residents Translating pharmacogenetic findings into clinical practice guidelines His recent publications demonstrate a strong focus on applying pharmacogenomics to cancer therapy, transplant medicine, and cardiovascular care. Dr. Wiltshire's work often involves multi-institutional collaborations, particularly through the North Carolina Precision Health Collaborative, which aims to implement pharmacogenomics across healthcare systems in North Carolina. Among his notable scientific contributions are: Development of prediction models for chemotherapy-induced toxicity Research on pharmacogenomic applications in hematopoietic stem cell transplant Studies examining the feasibility of pharmacogenetics in nursing home settings Work on rare genetic variants affecting drug metabolism Dr. Wiltshire has received research funding for his work in pharmacogenomics implementation and has contributed to educational initiatives in precision medicine. His laboratory collaborates with clinicians across multiple specialties to translate pharmacogenetic knowledge into practical clinical applications that improve patient outcomes.

Jiawei ZhouView profile

Assistant Professor

• Pharmacometrics
• Quantitative Clinical Pharmacology
• Machine Learning in Pharmacology
• +7 more

Jiawei Zhou is a Tenure-Track Assistant Professor in the Division of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy and a member of the UNC Lineberger Comprehensive Cancer Center. Her research integrates pharmacometrics, machine learning, and experimental pharmacology to advance translational drug development and precision medicine, with particular focus on oncology applications. Dr. Zhou earned her PhD from UNC and a B.S. in Pharmaceutical Sciences from Tsinghua University. Prior to joining the faculty in December 2024, she worked in the pharmaceutical industry as a clinical pharmacometrician, contributing to late-stage drug development across multiple therapeutic areas, including COVID-19 mRNA vaccine programs. Her research program focuses on three main areas: (1) Revolutionizing Patient-Reported Outcomes (PRO) Analysis with Population Modeling to enhance clinical decision-making; (2) Integrating AI into Pharmacometrics to automate code generation and improve model selection; and (3) Advancing Translational Science for Complex Therapeutics like mRNA-LNP platforms through quantitative PK/PD modeling. These efforts bridge computational and experimental approaches to accelerate drug development and optimize patient care. Analysis of her recent publications (2021-2025) reveals a clear trajectory toward more sophisticated integration of machine learning with traditional pharmacometric approaches, with growing emphasis on patient-centered outcomes and complex therapeutic modalities like mRNA-LNP systems. Her work spans oncology, supportive care, and vaccine development, demonstrating remarkable versatility while maintaining a strong methodological foundation in quantitative pharmacology. Dr. Zhou has received numerous honors and awards, including: Early Career Researcher Award from PharmAlliance (2025) Travel Award from Society for Industrial and Applied Mathematics (2022) Multiple awards from UNC-Chapel Hill including the J. Heyward Hull Award and GSK Fellowship Student Poster Awards from professional societies She mentors several graduate students and research assistants across multiple disciplines, including biostatistics, mathematics, and pharmaceutical sciences. Her lab has secured funding through competitive fellowships and awards, including the PharmAlliance Early Career Researcher Award. Dr. Zhou actively collaborates with researchers across UNC and with pharmaceutical industry partners. The Zhou Lab at UNC Eshelman School of Pharmacy brings together quantitative clinical pharmacologists, data scientists, and experimental pharmacologists to develop and apply innovative approaches that bridge computational modeling with in vivo and in vitro studies. The lab culture emphasizes both methodological rigor and translational impact, with projects spanning from basic method development to clinical applications.

• Pharmacometrics
• Population PKPD Modelling
• Clinical Pharmacology
• +4 more

Trine Meldgaard Lund serves as an Associate Professor in the Department of Drug Design and Pharmacology within the Faculty of Health and Medical Sciences at the University of Copenhagen. Her research focuses on optimizing pharmacotherapy and clinical trial designs through advanced pharmacometric modeling. With 85 research outputs and active collaborations across multiple countries, she maintains a significant international research presence. Her primary research domain centers on Population PKPD modelling and Pharmacometrics, specifically characterizing pharmacokinetic-pharmacodynamic relationships to identify sources of drug response variability. Key projects include fixed-dose combination development, model-based dose finding, PK meta-modeling of morphine, and investigating CYP enzyme differences in pediatric populations. Her work demonstrates strong translational impact through clinical pain trials and therapeutic drug monitoring applications. Lund's research portfolio shows consistent output in high-impact journals, with recent 2025 publications spanning nephrology, oncology, geriatric pharmacology, and cannabinoid therapeutics. Her work frequently addresses methodological challenges in clinical trial design and demonstrates particular expertise in modeling complex drug interactions and age-related pharmacokinetic variability. The collaborative nature of her research is evident through extensive co-authorship networks across Scandinavian institutions. As an educator, Lund teaches Pharmacokinetics and Pharmacodynamics across multiple courses including Basic Pharmacology, Principles of Pharmacology, and Organ-related Pharmacology. She also leads specialized elective courses and PhD-level instruction through the MIND program. Her academic leadership extends to organizing 9 significant professional activities including symposia on precision medicine, clinical trial design, and therapeutic drug monitoring for major Danish pharmacological societies.

Veronika WingstedtView profile

Researcher

• Nuclear Medicine
• Molecular Imaging
• Radiopharmaceutical Chemistry
• +3 more

Veronika Wingstedt serves as a Researcher within the Department of Medicinal Chemistry at Uppsala University, where she contributes to the Platform for Preclinical PET-MRI. Her technical expertise focuses on engineering advanced imaging protocols for biomedical research, specifically in the development and application of multimodal imaging techniques including PET, SPECT, and CT for preclinical disease modeling and drug evaluation. Her core research spans Nuclear Medicine , Molecular Imaging , and Radiopharmaceutical Chemistry , with specialized contributions in radiotracer synthesis (particularly C-11 and Ga-68 compounds), bone regeneration imaging, cancer theranostics, and endocrine disorder diagnostics. She integrates radiochemistry with molecular biology to develop imaging probes for bone morphogenetic protein tracking, insulinoma detection, and HER2-targeted prostate cancer therapy, emphasizing translational applications from preclinical validation to clinical feasibility studies. Analysis of her publication timeline (2012-2018) reveals consistent innovation in multimodal imaging probe development, with increasing focus on theranostic applications. Her work demonstrates methodological rigor in dosimetry calculations, radiolabeling optimization, and validation of imaging protocols across diverse disease models. Key thematic threads include the engineering of tri-modal visualization systems, precision targeting of molecular pathways in cancer, and quantitative assessment of physiological processes like cerebral blood flow during surgical interventions. No scientific awards, fellowships, or medals are documented in the provided materials. The available information does not specify graduate student advising relationships or external grant funding, though her extensive collaborative publication record indicates active participation in multidisciplinary research teams. As a core technical contributor to Uppsala University's Platform for Preclinical PET-MRI, Wingstedt supports biomedical research through state-of-the-art imaging infrastructure. This platform enables high-resolution quantitative studies across oncology, endocrinology, and bone disease research, with her engineering expertise directly enhancing capabilities in radiotracer development, multimodal imaging protocol design, and preclinical model validation.

Beth Apsel WingerView profile

Assistant Clinical Professor

• Precision Medicine
• Cancer Therapeutics
• Pharmacogenomics
• +3 more

Beth Apsel Winger is a clinical researcher at the University of California San Francisco (UCSF), focusing on precision medicine for cancer and blood diseases. Her work bridges targeted therapies and pharmacokinetics to optimize drug dosing. Education: BA in Chemistry (Yale), PhD in Chemistry & Chemical Biology (UCSF), MD (UCSF), Residency in Pediatrics (UCSF), Fellowship in Pediatric Hematology/Oncology (UCSF) Her research explores kinase mutations to expand targeted therapies and precision dosing strategies for individualized treatment. Recent work includes genomic sequencing applications in leukemia and pharmacokinetic modeling for pediatric transplantation. Scientific Awards include the Fulbright Graduate Student Award, St. Baldrick's Foundation Fellowship, Mary Anne Koda-Kimble Award for Innovation, and Helen Diller Family Comprehensive Cancer Center Junior Clinical Investigator Award. She collaborates on grants and clinical initiatives , such as the LEAP Consortium for pediatric leukemia therapies and precision dosing platforms. Her expertise spans pediatric hematology/oncology , molecular oncology , and pharmacogenomics .